Ingersoll Rand (IR) Citi's Global Industrial Tech & Mobility Conference 2026 summary

Strategic achievements and growth

• Completed 76 global acquisitions since the merger, driving portfolio expansion and reinforcing an ownership-driven culture among 20,000+ employees.

• Achieved solid organic growth, improved margins, and strong free cash flow, with $1.2–$1.3 billion generated annually in recent years.

• Maintains a robust M&A pipeline, with 16 deals in 2025 and expectations for similar activity in 2026, focusing on bolt-ons and select larger acquisitions.

• Life sciences and precision technologies businesses are key growth drivers, with life sciences showing mid-teens order growth and sustained margins above 30%.

• Recurring revenue has grown from $200 million in 2023 to $450 million in 2026, with a $1 billion target for 2027 and $1.1 billion in future contracts already secured.

Regional performance and market dynamics

• China now represents 10–11% of revenue, down from 15% two to three years ago, but has stabilized with low single-digit organic order growth and strong execution in a competitive market.

• Non-China APAC regions, including Korea, Australia, and Southeast Asia, saw 20% organic order growth in Q4, supported by targeted investments and new manufacturing facilities in India and Brazil.

• Europe has been the most stable region over the past 18 months, with momentum in France, Italy, and Spain, driven by sustainability and both short- and long-cycle projects.

• India continues to deliver double-digit growth, supported by new facilities and bolt-on acquisitions, while the Americas show positive trends in life sciences, reshoring, and energy efficiency.

Financial guidance and operational focus

• Organic growth guidance for 2026 is set at 0–2%, reflecting a prudent approach amid ongoing market uncertainty and a desire to see sustained momentum before revising expectations.

• Margin expansion remains a focus, with ITS maintaining ~29% EBITDA margins despite headwinds, and PST targeting mid-30s EBITDA margins by 2027 through restructuring, productivity, and life sciences growth.

• Pricing actions are offsetting tariff impacts, with expectations for margin expansion in the second half of 2026 as productivity and restructuring benefits materialize.

• Investments continue in innovation, R&D, commercial resources, and recurring revenue, with a commitment to reinvest for sustainable growth.